Novo Nordisk and AI-driven protein design company Gensaic are to develop tissue-targeted therapies for cardiometabolic ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

Nucresiran and Vutrisiran Advancements Demonstrate Durable Leadership in TTR Alnylam scientists will provide an update on the TRITON Phase 3 program for its next-generation transthyretin (TTR ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

We’re ahead of what our projections were. And the evolution of events, we expect to be similar to the other recent studies, acoramidis and vutrisiran. So now there is a lot of data available on ...

Patients may present with polyneuropathy (PN), cardiomyopathy (CM), or both manifestations of disease. Vutrisiran is an RNAi therapeutic that delivers rapid knockdown of mutant and wild?type TTR, ...